Creative Touch Permanent Makeup and Aesthetics

Tumour necrosis factor alpha (TNF-α) is a pro-inflammatory cytokine produced by macrophages, adipocytes, and T-cells that acts through NF-κB to amplify and sustain inflammatory signalling. In skin, it operates across three axes: it suppresses filaggrin and loricrin expression via the FRA1:c-JUN:HDAC1 complex and JNK activation, compromising barrier integrity; it drives type I collagen degradation through MMP-1/ MMP-3 upregulation, accelerating dermal ageing; and it induces serine phosphorylation of IRS-1, blocking insulin receptor signalling and creating peripheral insulin resistance in obesity. In psoriasis it is a primary pathogenic driver and the target of anti-TNF biologic therapies. TNF-α is not directly targeted in aesthetic practice but is a consistently relevant upstream driver of barrier failure, collagen loss, and skin quality decline.

TNF-α is released in response to cellular stress, infection, injury, or sustained metabolic dysfunction. It signals through two cell-surface receptors – TNFR1 (ubiquitously expressed) and TNFR2 (primarily immune cells and endothelium) – activating the NF-κB transcription factor pathway as its primary downstream signal. NF-κB activation drives a pro-inflammatory gene expression programme: upregulation of IL-1β, IL-6, IL-8, COX-2, and additional TNF-α itself, creating an amplification loop that sustains inflammation beyond the initial trigger. In skin, this downstream cascade operates across three clinically relevant axes. nature.com

Barrier Protein Suppression

TNF-α directly suppresses the expression of filaggrin (FLG) and loricrin (LOR) – the two principal structural proteins of the stratum corneum. The mechanism involves TNF-α (synergistically with IFN-γ) promoting formation of the FRA1:c-JUN:HDAC1 transcriptional repressor complex, which binds the filaggrin gene promoter and inhibits its transcription. ^[1] TNF-α additionally downregulates filaggrin and loricrin through c-Jun N-terminal kinase (JNK) activation – a Smad-independent pathway that reduces barrier protein synthesis independently of the FRA1 complex. ^[5] The functional consequence is a thinner, protein-depleted stratum corneum with elevated TEWL – the same pattern observed in both psoriasis and atopic dermatitis, where TNF-α is chronically elevated. This connects TNF-α directly to the barrier disruption cycle: reduced filaggrin → elevated TEWL → increased allergen and irritant penetration → further immune activation → further TNF-α production.

Collagen Degradation

TNF-α drives type I collagen degradation in human skin through a two-step MMP activation mechanism. It upregulates MMP-1 secretion and induces MMP-3 production, which acts as an endogenous activator of MMP-1’s collagenolytic activity – the combination producing significantly accelerated type I collagen degradation compared to either agent alone. ^[7] TNF-α also activates pro-MMP-2 through NF-κB-dependent induction of MT1-MMP (membrane type 1 MMP) in fibroblasts embedded in collagen matrix, providing a parallel pathway for ECM degradation. ^[2] The net effect is accelerated collagen turnover weighted toward degradation over synthesis – the same imbalance that characterises photoaged skin and chronically inflamed skin conditions, and that explains why sustained systemic TNF-α elevation from adipose inflammation contributes to accelerated dermal ageing independent of UV exposure.

Insulin Resistance and the Metabolic-Skin Axis

Adipose tissue is not merely a passive energy store – it is an active endocrine organ, and hypertrophied adipocytes in obesity secrete substantially elevated TNF-α into the systemic circulation. TNF-α induces serine phosphorylation of insulin receptor substrate-1 (IRS-1) in adipocytes, muscle, and liver cells, converting IRS-1 from a positive mediator of insulin receptor signalling into an inhibitor – blocking the tyrosine kinase activity of the insulin receptor and preventing downstream glucose uptake signalling. ^[3] This is the primary molecular mechanism by which adipose inflammation in obesity creates peripheral insulin resistance – establishing TNF-α as the biochemical link between excess adiposity and type 2 diabetes risk. For skin, the consequence is a dual pathway of damage: direct MMP-driven and filaggrin-suppressive effects on the dermis and epidermis, compounded by the glycation, AGE accumulation, and IGF-1 dysregulation that accompany insulin resistance and elevated blood glucose.

TNF-α in Psoriasis

Psoriatic lesions are characterised by substantially elevated TNF-α produced by keratinocytes, dermal macrophages, and T-lymphocytes. TNF-α drives the keratinocyte hyperproliferation and defective differentiation of psoriatic plaques through NF-κB activation, and synergises with IL-17A – the other primary psoriatic cytokine – to amplify chemokine production, neutrophil recruitment, and the self-sustaining inflammatory loop of the psoriatic plaque. ^[6] The clinical validation of TNF-α’s central role in psoriasis pathogenesis comes from the therapeutic success of anti-TNF biologics – etanercept, adalimumab, infliximab – which produce substantial plaque clearance by neutralising TNF-α bioavailability, dismantling the TNF-α/IL-17A synergy that sustains plaque inflammation before T-cell numbers or keratinocyte differentiation patterns visibly normalise. ^[4]